ESMO 2023 | Optimal duration of immunotherapy administration for patients with NSCLC

Benjamin Besse, MD, PhD, Gustave Roussy, Villejuif, France, discusses the long-debated topic of the duration of immunotherapy for non-small cell lung cancer (NSCLC). Dr Besse elaborates on trials within this field, including the Phase III CHECKMATE-153 (NCT02066636), DICIPLE (NCT03469960) and GEMSTONE-301 (NCT03728556) trials. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.